BioCentury
ARTICLE | Distillery Therapeutics

Cancer

April 11, 2017 8:03 PM UTC

Mouse studies suggest inhibiting CD47 could help treat pediatric brain tumors. In orthotopic xenograft mouse models of five subtypes of pediatric brain cancer -- medulloblastoma, atypical teratoid rhabdoid tumor, primitive neuroectodermal tumor, glioblastoma and diffuse intrinsic pontine glioma (DIPG) --, the anti-CD47 mAb Hu5F9-G4 decreased tumor growth and increased survival compared with vehicle. Next steps could include testing CD47 inhibitors in other subtypes of brain cancer.

Forty Seven Inc. and Stanford University have Hu5F9-G4 in Phase I testing to treat acute myelogenous leukemia (AML) and solid tumors. ...

BCIQ Target Profiles

CD47